Table 1 Baseline characteristics on admission to the hospital of patients with low MxA, intermediate MxA and high MxA

Female gender, n/N (%)

18/36 (50%)

31/73 (43%)

66/159 (42%)

0.647^{^}

Age (years)

61

58

58

0.874^#

Q1–Q3

48–71

44–69

48–69

BMI (kg/m²)

27.1

30.1

29.9

0.237^#

Q1–Q3

24.0–31.8

26.1–34.6

27.0–34.5

Smoking status, n/N (%)

0.306^{^}

Non-smoker

16/26 (62%)

39/64 (61%)

71/133 (53%)

Ex-smoker

7/26 (27%)

20/64 (31%)

56/133 (42%)

Smoker

3/26 (12%)

5/64 (8%)

6/133 (5%)

Vaccination for COVID-19

0.563^{^}

Unvaccinated

36/36 (100%)

71/73 (97%)

154/159 (97%)

Partially vaccinated

0/36 (0%)

2/73 (3%)

5/159 (3%)

SARS-CoV-2-specific IgG (%), n/N (%)

24/30 (80%)

30/61 (49%)

61/138 (44%)

0.002^{^}

Native SpO₂ (%)

96

95

94

 < 0.001^#

Q1–Q3

95–98

92–96

89–96

Temperature (°C)

37.5

37.9

38.2

0.012#

Q1–Q3

37.2–38.4

37.4–38.5

37.6–38.7

Blood lymphocytes (× 10⁹/L)

1.23

0.99

1.05

0.583#

Q1–Q3

0.70–1.53

0.72–1.21

0.71–1.31

CRP (mg/L)

40

48

64

0.128^#

Q1–Q3

14–109

17–107

36–106

PCT (μg/L)

0.09

0.12

0.14

0.017^#

Q1–Q3

0.05–0.19

0.65–0.24

0.07–0.32

Interleukin-6 (ng/L)

11.3

18.7

36.9

 < 0.001^#

Q1–Q3

3.9–55.4

7.2–54.1

15.7–80.3

Ferritin (μg/L)

573

678

629

0.354^#

Q1–Q3

243–838

257–1225

337–1037

Pre-existent comorbidities, n/N (%)

 Obesity

13/29 (45%)

29/58 (50%)

73/147 (50%)

0.883^{^}

 Hypertension

11/36 (31%)

27/73 (37%)

59/159 (37%)

0.751^{^}

 Diabetes Mellitus

6/36 (17%)

15/73 (21%)

43/159 (27%)

0.309^{^}

 Obstructive Sleep Apnea

5/36 (14%)

9/73 (12%)

28/159 (18%)

0.561^{^}

 Asthma

5/36 (14%)

8/73 (11%)

19/159 (12%)

0.906^{^}

 COPD

0/36 (0%)

4/73 (6%)

11/159 (7%)

0.264^{^}

Home medication, n/N (%)

 Immunosuppressive

2/36 (6%)

2/73 (3%)

18/156 (12%)

0.065^

 Biological

1/35 (3%)

2/73 (3%)

2/156 (1%)

0.680^

 Cytostatic

0/35 (0%)

0/73 (0%)

2/156 (1%)

0.498^